Full Press Release Details
Informs That An Application To
a Class Action Against 26 Cannabis
in Israel, Including InterCure,
Filed to The Court In Israel
YORK, TORONTO, and HERZLIYA, Israel - April 25, 2023 - InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR)
(dba Canndoc) ("InterCure" or the "Company"), the leading cannabis company outside of North America,
announces that on April 23, 2023, it was informed that an application for approval of a class action in Israel was filed against twenty-six
defendants, among them the leading cannabis groups in Israel, including the Company and three of its subsidiaries.
subject of the application is the alleged claim that the defendants are in violation of the advertising prohibitions included in the
Israeli regulations overseeing medical cannabis in Israel.
Company is currently considering the application and its likelihood of acceptance.
InterCure (dba Canndoc)
(dba Canndoc) (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North
America. Canndoc, a wholly owned subsidiary of InterCure, is Israel's largest licensed cannabis producer and one of the first to
offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market
leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale"
model to lead the fastest growing cannabis global market outside of North America.
more information, visit: http://www.intercure.co.
Cohen, Chief Financial Officer